Plain-English translation of NCT06487039 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new eye drop called to see if it can help treat wet age-related macular degeneration (nAMD), a condition where abnormal blood vessels grow under the retina and damage vision. Researchers want to find out if this medication is safe and works well for people with this condition. You would receive the medication four times a day for 12 weeks while doctors monitor your eye health.
Current treatments for wet age-related macular degeneration often require injections directly into the eye, which can be uncomfortable and inconvenient for patients. This trial is exploring whether an eye drop version could offer a simpler, less invasive way to treat this serious vision condition.
You likely qualify if…
You likely don't qualify if…
You would visit the study clinic multiple times over 12 weeks to receive the medication and have your eyes examined. You would instill the eye drops four times daily at home. Doctors would check how well the treatment works and monitor for any side effects at visits at weeks 2, 4, 8, and 12, with one final follow-up visit 4 weeks after stopping the medication. If you do not respond well to the treatment at any point, you would be offered a standard injection treatment and withdrawn from the study.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
South Korea